# US 2023/0054551 A1 · Oral pharmaceutical composition and method for delivering nitric oxide to a patient's circulatory system or brain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054551 A1
- Document ID: US20230054551A1
- Status: Published application
- Kind: A1
- Application number: 17/579,053
- Filed: 2022-01-19
- Published: 2023-02-23
- Earliest claimed: 2021-08-07
- Assignees: National Tsing Hua University
- Applicants: National Tsing Hua University
- Inventors: Tsai-Te LU; Cheng-Ru WU
- Web page: https://patentgrep.com/patent/US20230054551A1

## CPC

- A61K 31/295: Iron group metal compounds
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition for oral administration and a use of a pharmaceutical composition for preparing oral medication for delivering nitric oxide to the patient's circulatory system or brain are provided. The pharmaceutical composition mainly includes a dinitrosyl iron complex and a pharmaceutically acceptable excipient. The pharmaceutical composition delivers nitric oxide to the patient's circulatory system or brain to stimulate neurogenesis or regulate blood sugar.

## Claims

### Claim 1

An oral pharmaceutical composition, comprising a double nitroso iron complex of formula (I), and a pharmaceutically acceptable excipient:
wherein R represents a C1-C5 hydroxyl group.

### Claim 2 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient is at least one selected from a group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and mixture thereof.

### Claim 3 (depends on 2)

The oral pharmaceutical composition of claim 2, wherein a dosage form of the oral pharmaceutical composition is a tablet, a capsule, or an oral solution.

### Claim 4 (depends on 1)

The oral pharmaceutical composition of claim 1, wherein R represents a C2 hydroxyl group.

### Claim 5 (depends on 1)

A method for delivering nitric oxide to a patient's circulatory system or brain, comprising:
orally administering the oral pharmaceutical composition of claim 1 to the patient.

### Claim 6 (depends on 5)

The method of claim 5, wherein delivering nitric oxide to a patient's circulatory system or brain for stimulating neurogenesis or regulating blood sugar.

### Claim 7 (depends on 5)

The method of claim 5, wherein delivering nitric oxide to a patient's circulatory system or brain for stimulating neurogenesis refers to a treatment of a neurodegenerative disease or an ischemic stroke.

### Claim 8 (depends on 7)

The method of claim 7, wherein the neurodegenerative disease is at least one selected from a group consisting of amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), frontotemporal dementia (FTD), spinocerebellar ataxias (SCA), Machado-Joseph disease (MJD), Dentatorubropallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA), and fragile X-associated tremor and ataxia syndrome (FXTAS).

### Claim 9 (depends on 6)

The method of claim 6, wherein regulating blood sugar refers to a treatment of diabetes.
